DE69738905D1 - Methoden und zusammensetzungen zur transformation von zellen - Google Patents

Methoden und zusammensetzungen zur transformation von zellen

Info

Publication number
DE69738905D1
DE69738905D1 DE69738905T DE69738905T DE69738905D1 DE 69738905 D1 DE69738905 D1 DE 69738905D1 DE 69738905 T DE69738905 T DE 69738905T DE 69738905 T DE69738905 T DE 69738905T DE 69738905 D1 DE69738905 D1 DE 69738905D1
Authority
DE
Germany
Prior art keywords
cell
sequences
transformation
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738905T
Other languages
English (en)
Inventor
Philippe Leboulch
Eric Bouhassira
Karen Westerman
Ken Julian Takekoshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Massachusetts Institute of Technology
Original Assignee
Albert Einstein College of Medicine
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24664451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69738905(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Albert Einstein College of Medicine, Massachusetts Institute of Technology filed Critical Albert Einstein College of Medicine
Application granted granted Critical
Publication of DE69738905D1 publication Critical patent/DE69738905D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69738905T 1996-06-14 1997-06-06 Methoden und zusammensetzungen zur transformation von zellen Expired - Lifetime DE69738905D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66408496A 1996-06-14 1996-06-14
US08/743,796 US5928914A (en) 1996-06-14 1996-11-05 Methods and compositions for transforming cells
PCT/US1997/009954 WO1997047758A1 (en) 1996-06-14 1997-06-06 Methods and compositions for transforming cells

Publications (1)

Publication Number Publication Date
DE69738905D1 true DE69738905D1 (de) 2008-09-25

Family

ID=24664451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738905T Expired - Lifetime DE69738905D1 (de) 1996-06-14 1997-06-06 Methoden und zusammensetzungen zur transformation von zellen

Country Status (9)

Country Link
US (1) US5928914A (de)
EP (1) EP0914457B1 (de)
JP (2) JP2000512150A (de)
AT (1) ATE404684T1 (de)
AU (1) AU733016B2 (de)
CA (1) CA2258007A1 (de)
DE (1) DE69738905D1 (de)
HK (1) HK1020752A1 (de)
WO (1) WO1997047758A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226463A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Recombinational cloning using engineered recombination sites
US6720140B1 (en) * 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US6143557A (en) 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6964861B1 (en) 1998-11-13 2005-11-15 Invitrogen Corporation Enhanced in vitro recombinational cloning of using ribosomal proteins
US5928914A (en) * 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
US6534314B1 (en) * 1996-06-14 2003-03-18 Massachusetts Institute Of Technology Methods and compositions for transforming cells
US5851808A (en) * 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
DE69840439D1 (de) 1997-04-24 2009-02-26 Univ Washington Zielgerichtete genveraenderung mit parvoviralen vektoren
US20030124555A1 (en) * 2001-05-21 2003-07-03 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
JP4303418B2 (ja) * 1997-10-24 2009-07-29 ライフ テクノロジーズ コーポレーション 組換え部位を有する核酸を使用する組換えクローニング
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
US7102055B1 (en) * 1997-11-18 2006-09-05 Pioneer Hi-Bred International, Inc. Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
AU745960C (en) 1997-11-18 2003-09-18 Pioneer Hi-Bred International, Inc. A novel method for the integration of foreign DNA into eukaryoticgenomes
ES2338284T3 (es) 1997-11-18 2010-05-05 Pioneer Hi-Bred International, Inc. Movilizacion de genomas viricos a partir de t-adn utilizando sistemas de recombinacion especificos de sitio.
DK1034262T3 (da) 1997-11-18 2005-11-28 Pioneer Hi Bred Int Sammensætninger og fremgangsmåder til genetisk modifikation af planter
EP0939120A1 (de) 1998-02-27 1999-09-01 Gesellschaft für biotechnologische Forschung mbH (GBF) Methode zum marker-freien, wiederholten Austausch von DNA-Expressionskassetten im Genom von Zellen oder Bestandteilen davon
WO2000024917A1 (en) * 1998-10-28 2000-05-04 University Of Washington Targeted gene modification by parvoviral vectors
DE60042969D1 (de) 1999-03-02 2009-10-29 Life Technologies Corp Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
EP2031068A1 (de) * 1999-07-14 2009-03-04 Transgenic Inc. Fallenvektor und Gen-Trapping-Verfahren damit
EP1194540A1 (de) * 1999-07-14 2002-04-10 Clontech Laboratories Inc. Rekombinase-basierende methoden zur herstellung von expressionsvektoren und zusammensetzungen für ihre verwendung
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
ATE391789T1 (de) 1999-12-10 2008-04-15 Invitrogen Corp Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
WO2001066717A2 (en) * 2000-03-03 2001-09-13 The University Of Utah Gene targeting method
US7244560B2 (en) * 2000-05-21 2007-07-17 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6551828B1 (en) * 2000-06-28 2003-04-22 Protemation, Inc. Compositions and methods for generating expression vectors through site-specific recombination
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7560622B2 (en) 2000-10-06 2009-07-14 Pioneer Hi-Bred International, Inc. Methods and compositions relating to the generation of partially transgenic organisms
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030077804A1 (en) * 2001-04-19 2003-04-24 Invitrogen Corporation Compositions and methods for recombinational cloning of nucleic acid molecules
ES2350248T3 (es) 2001-10-01 2011-01-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Procedimiento de producción de bibliotecas de proteínas y de selección de proteínas a partir de las mismas.
AU2002356891A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Method and system for inducible recombinational cloning in bacterial cells
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US7164056B2 (en) 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
CA2497913C (en) 2002-09-05 2014-06-03 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
TW200502390A (en) 2002-11-28 2005-01-16 Peter Droege Sequence specific DNA recombination in eukaryotic cells
EP1644538A4 (de) * 2003-06-26 2006-11-08 Invitrogen Corp Verfahren und zusammensetzungen zum nachweis von promotoraktivität und zur expression von fusionsproteinen
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
EP1697534B1 (de) 2003-12-01 2010-06-02 Life Technologies Corporation Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
AU2007219615B2 (en) 2006-03-03 2013-11-28 Promis Neurosciences Inc. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
BRPI0711207A2 (pt) * 2006-05-22 2011-03-22 Hiprocell Llc vetor alvo para intregação em sìtios-especificos, método de sìtio-especìfico que integra um polinucleotìdeo codificando uma proteina de interesse em um genoma de uma célula eucariótia, célula eucariótica isolada , kit para uso no sìtio-especìfico que integra um polinucleotideo dentro de um genoma de uma celula in vitro e kit para uso em produzir uma proteìna em célula
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
EP3293266A1 (de) 2007-05-04 2018-03-14 University Health Network Il-12-immuntherapie gegen krebs
WO2009114942A1 (en) 2008-03-20 2009-09-24 University Health Network Thymidylate kinase fusions and uses thereof
WO2010117464A1 (en) * 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
WO2014078819A2 (en) 2012-11-16 2014-05-22 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
CA2989827A1 (en) 2015-06-17 2016-12-22 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1293460C (en) * 1985-10-07 1991-12-24 Brian Lee Sauer Site-specific recombination of dna in yeast
EP0300422B1 (de) * 1987-07-21 1992-12-02 The Du Pont Merck Pharmaceutical Company Verfahren für die Herstellung von in tierischen Zellen stabilen und lebensfähigen rekombinanten viralen Vektoren
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
EP0626999A4 (en) * 1992-01-24 1997-04-09 Life Technologies Inc Modulation of enzyme activities in the -i(in vivo) cloning of dna.
FR2737731B1 (fr) * 1995-08-07 1997-10-10 Pasteur Institut Sequence de retroelements naturels ou synthetiques ayant pour fonction de permettre l'insertion de sequences nucleotidiques dans une cellule eucaryote
US5928914A (en) * 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells

Also Published As

Publication number Publication date
WO1997047758A1 (en) 1997-12-18
JP2010063463A (ja) 2010-03-25
AU3306297A (en) 1998-01-07
AU733016B2 (en) 2001-05-03
JP5765547B2 (ja) 2015-08-19
CA2258007A1 (en) 1997-12-18
HK1020752A1 (en) 2000-05-19
ATE404684T1 (de) 2008-08-15
JP2000512150A (ja) 2000-09-19
EP0914457B1 (de) 2008-08-13
EP0914457A1 (de) 1999-05-12
US5928914A (en) 1999-07-27

Similar Documents

Publication Publication Date Title
DE69738905D1 (de) Methoden und zusammensetzungen zur transformation von zellen
Lee et al. Role of nucleotide sequences of loxP spacer region in Cre-mediated recombination
ATE296356T1 (de) Methode zur spezifischen integration von genen in säugetierzellen durch homologe rekombination, und vektoren zu deren durchführung
ATE317440T1 (de) Neuartige methode zur integration von fremd-dna ins eukaryotische genom
DE69427997T2 (de) Hybrider mensch/tier faktor viii
CA2203569A1 (en) Nucleotide sequence encoding the enzyme i-scei and the uses thereof
WO1999015682A3 (en) Gene silencing materials and methods
DK0506945T3 (da) Fremgangsmåde til genoverførsel under anvendelse af retrotransposoner
TR199903234T2 (xx) Erkek doku tercih edilen d�zenleyici b�lge ve kullan�m�.
ATE280239T1 (de) Homologe rekombination in eukaryotischen zellen mit inaktiviertem fehlpaarungsreparatur-system
WO2002088353A3 (en) Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof
TR199802503A2 (xx) Endojen gen aktivasyonu i�in h�crelerin optimizasyonu.
ATE526818T1 (de) Gentechnisch hergestellte wasserlinse
Henningfeld et al. A model for topoisomerase I-mediated insertions and deletions with duplex DNA substrates containing branches, nicks, and gaps
EA199800324A1 (ru) Улучшенное встраивание экзогенной днк, введенной в эукариостические клетки
ATE290094T1 (de) Retrovirale pseudotyp-vektoren mit modifizierten oberflächen-hüllproteinen und verfahren zu ihrer herstellung für den selektiven gentransfer
AU3790300A (en) Methods for the preparation of nucleic acid and polypeptide libraries and uses thereof
WO2002000871A3 (de) Verfahren zur einbringung von nukleinsäuren und anderen biologisch aktiven molekülen in der kern höherer eukaryontischer zellen mit hilfe elektrischen stroms
EP2281892A3 (de) Verfahren zur Herstellung von Polypeptiden in atmungsdefizienten Trichoderma Zellen
GB2321702B (en) Methods and means relating to retrotransposon and retroviral integration
ES2109194A1 (es) Un procedimiento para producir la enzima d-aminoacido oxidasa de rhodotorula gracilis en celulas hospedantes.
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
ATE259421T1 (de) Dna-virus-vektoren und verfahren zu ihrer herstellung
McAuslan Virus-associated enzymes
WO2002036760A3 (en) Methods for expressing endogenous genes by restriction enzyme mediated integration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition